Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Top Page
CytomX Therapeutics
(NASDAQ:CTMX)54Neutral
Positive Factors
Financial Performance
CytomX reported its FY2024 financials, recording a net profit of $0.38 per share for the period vs. prior estimate of net profit of $0.14 per share.
Pipeline Development
CytomX announced a corporate restructuring and revealed its pipeline priorities, with CX-2051 development in colorectal cancer taking the lead.
Negative Factors
Pipeline Setbacks
CX-904 discontinuation adds to history of pipeline setbacks.
CytomX Therapeutics (CTMX) vs. S&P 500 (SPY)
Market Cap
$48.14M
Dividend YieldN/A
Average Volume (3M)685.94K
Price to Earnings (P/E)3.6
Beta (1Y)1.65
Revenue Growth33.66%
EPS GrowthN/A
CountryUS
Employees122
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)0.17
Shares Outstanding78,258,880
10 Day Avg. Volume679,442
30 Day Avg. Volume685,941
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.38
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.69Price Target Upside610.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
CytomX Therapeutics Business Overview & Revenue Model
Company DescriptionCytomX Therapeutics, Inc. is a biotechnology company that specializes in the development of novel therapeutics for the treatment of cancer and other serious diseases. The company is headquartered in South San Francisco, California, and operates primarily in the pharmaceutical and biotechnology sectors. CytomX is known for its proprietary Probody platform, which is designed to create therapies that remain inactive until they reach the tumor microenvironment, thereby minimizing off-target effects and enhancing safety and efficacy.
How the Company Makes MoneyCytomX Therapeutics generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales of products developed using its Probody platform. Key collaborations include alliances with industry leaders such as Bristol-Myers Squibb, AbbVie, and Amgen, among others. Additionally, the company may engage in research and development grants and contracts that contribute to its revenue stream. The success and progression of its proprietary drug candidates through clinical trials also play a critical role in attracting further investment and partnership opportunities.
CytomX Therapeutics Financial Statement Overview
Summary
CytomX Therapeutics shows promising revenue growth with a high gross margin, indicating operational improvements. However, negative equity and cash flow challenges present significant financial risks that must be addressed for sustainable growth.Income Statement
CytomX Therapeutics has demonstrated a significant improvement in revenue with a 25.07% increase in TTM (Trailing-Twelve-Months) compared to the previous year. The gross profit margin is exceedingly high at 98.88%, indicating effective cost management. However, the net profit margin of 10.92% reflects moderate profitability, with potential for further improvement. The EBIT and EBITDA margins are positive at 5.30% and 6.39% respectively, marking a turnaround from negative margins in prior years.65
Positive
Balance Sheet
The balance sheet reveals concerning aspects with negative stockholders' equity, resulting in an inability to calculate the debt-to-equity ratio. The return on equity also cannot be determined due to negative equity. The equity ratio is negative, indicating liabilities exceed assets, which poses a risk to financial stability despite a reduction in total liabilities over the years.30
Negative
Cash Flow
CytomX's cash flow statement shows a negative free cash flow growth rate, indicating a deteriorating cash position. The operating cash flow to net income ratio is negative, suggesting that operating activities are not generating sufficient cash relative to net income. The free cash flow to net income ratio is also negative, underlining cash flow challenges despite positive net income in the latest TTM.45
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 126.62M | 101.21M | 53.16M | 69.57M | 100.36M | 57.49M | Gross Profit |
| 125.20M | 101.21M | 47.31M | 63.73M | 100.36M | 57.49M | EBIT |
| 6.71M | -6.48M | -101.33M | -83.78M | -48.60M | -110.89M | EBITDA |
| 8.09M | -4.31M | -98.89M | -113.34M | -77.97M | -138.88M | Net Income Common Stockholders |
| 13.83M | -569.00K | -97.30M | -80.65M | -32.88M | -102.24M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 150.28M | 174.51M | 193.65M | 305.23M | 316.12M | 296.14M | Total Assets |
| 184.69M | 201.79M | 260.89M | 339.41M | 358.66M | 341.28M | Total Debt |
| 12.87M | 13.97M | 18.06M | 18.06M | 24.87M | 24.87M | Net Debt |
| -23.31M | -3.20M | -175.59M | -187.47M | -166.99M | -163.55M | Total Liabilities |
| 216.37M | 249.24M | 346.64M | 250.03M | 308.86M | 290.17M | Stockholders Equity |
| -31.68M | -47.45M | -85.75M | 89.38M | 49.80M | 51.11M |
| Cash Flow | Free Cash Flow | ||||
| -88.78M | -56.88M | -112.53M | -120.64M | 2.95M | -143.98M | Operating Cash Flow |
| -88.29M | -56.03M | -110.79M | -119.03M | 5.26M | -140.48M | Investing Cash Flow |
| 97.43M | -150.67M | 98.26M | 22.49M | -18.72M | 79.70M | Financing Cash Flow |
| 5.52M | 30.23M | 648.00K | 110.21M | 16.89M | 1.63M |
CytomX Therapeutics Technical Analysis
Negative
0.66
Price Trends
0.86
Negative
0.96
Negative
1.15
Negative
Market Momentum
-0.07
Positive
35.65
Neutral
17.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.86, and below the 200-day MA of 1.15, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of 17.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTMX.
CytomX Therapeutics Risk Analysis
CytomX Therapeutics disclosed 72 risk factors in its most recent earnings report. CytomX Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CytomX Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $48.14M | 3.64 | -58.97% | ― | 33.66% | ― | |
52 Neutral | $5.66B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
44 Neutral | $125.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $255.57M | ― | -31.41% | ― | 389.82% | -22.66% | |
39 Underperform | $103.09M | ― | -54.21% | ― | -87.34% | 6.37% | |
37 Underperform | $52.35M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
CTMX
CytomX Therapeutics
0.66
-1.85
-73.71%
XOMA
Xoma
21.82
-4.46
-16.97%
FATE
Fate Therapeutics
1.01
-6.88
-87.20%
KPTI
Karyopharm Therapeutics
6.89
-15.31
-68.96%
BPMC
Blueprint Medicines
87.12
-2.35
-2.63%
ADAP
Adaptimmune Therapeutics
0.48
-1.06
-68.83%
CytomX Therapeutics Earnings Call Summary
Earnings Call Date: Mar 6, 2025 | % Change Since: 6.45% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in advancing clinical programs and strong financial performance, especially through strategic partnerships and increased revenue. However, challenges include the discontinuation of CX-904 and a decrease in cash reserves. Overall, the positive aspects slightly outweigh the negatives.Highlights
Advancement of Clinical Programs
In 2024, CytomX advanced two new programs, CX-2051 and CX-801, into the clinic, prioritizing these programs and streamlining the organization to extend the cash runway to Q2 2026.
Financial Performance
Total revenue for 2024 was $138.1 million, up from $101.2 million in 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron.
Pipeline Progress and Strategic Partnerships
CytomX achieved a $5 million milestone payment from Astellas and continues progress with partnerships involving Bristol Myers Squibb, Amgen, Moderna, and Regeneron.
Lowlights
Discontinuation of CX-904 Development
CytomX and Amgen jointly decided not to continue the development of CX-904 due to clinical observations and respective priorities.
Decrease in Cash Reserves
Cash reserves decreased from $174.5 million at the end of 2023 to $100.6 million at the end of 2024, despite the extension of the cash runway.
Company Guidance
In the fourth quarter of 2024 financial results call, CytomX Therapeutics provided detailed guidance on their pipeline progress and financial outlook. They highlighted the advancement of two new clinical programs, CX-2051 and CX-801, prioritizing these to optimize resource allocation and extending their cash runway to the second quarter of 2026. They aim to generate initial clinical data for both programs in 2025, with CX-2051 targeting colorectal cancer as a first-in-class ADC and CX-801 as a next-generation targeted immunotherapy. Financially, the company reported $138.1 million in revenue for 2024, an increase from $101.2 million in 2023, and ended the year with $100.6 million in cash, cash equivalents, and investments, compared to $174.5 million in 2023. The increase in revenue was attributed to collaborations with companies like Bristol Myers Squibb and Moderna. Total operating expenses for 2024 were $113.1 million, slightly up from $107.7 million in 2023, primarily due to a milestone payment to AbbVie.CytomX Therapeutics Corporate Events
Executive/Board Changes
CytomX Therapeutics Announces Executive Departure and Severance
Neutral
Feb 3, 2025
On January 30, 2025, CytomX Therapeutics announced the termination of employment for Jeffrey Landau, the Senior Vice President, Chief Business Officer, and Head of Strategy, effective February 7, 2025. The company has arranged a Separation Agreement that provides economic payments consistent with Mr. Landau’s prior severance agreement, and includes a general release of claims against the company.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.